Abstract: A method for manufacturing metal components includes the steps of providing a waste feedstock having a selected chemical composition; producing an additive manufacturing (AM) grade alloy powder from the waste feedstock using a cold hearth mixing process; providing an additive manufacturing system; controlling the producing of the alloy powder such that the properties of the alloy powder optimize building of the components using the additive manufacturing system; and building the components using the alloy powder and the additive manufacturing system.

Abstract: A method of delivering aerosolized surfactant to an infant that includes interfacing an aerosolization device with an airway of an infant and aerosolizing, using the aerosolization device, a volume of surfactant into particles having a mass mean aerodynamic diameter (MMAD) of less than about 3 ?m at a rate of at least 0.1 ml/min. The surfactant is aerosolized within about 1 to 8 cm from a patient interface. Aerosol is generated for up to approximately 80% or each inspiration. The method also includes delivering the aerosolized surfactant to the infant's airway.

Abstract: A method for manufacturing metal components includes the steps of providing a waste feedstock having a selected chemical composition; producing an additive manufacturing (AM) grade alloy powder from the waste feedstock using a cold hearth mixing process; providing an additive manufacturing system; controlling the producing of the alloy powder such that the properties of the alloy powder optimize building of the components using the additive manufacturing system; and building the components using the alloy powder and the additive manufacturing system.

Abstract: An aerosolization apparatus comprises a container containing a pharmaceutical formulation, the pharmaceutical formulation comprising an active agent and a propellant. The aerosolization apparatus further comprises a metering chamber in communication with the container, the metering chamber adapted to hold a metered amount of the pharmaceutical formulation, a valve to allow the metered amount of the pharmaceutical formulation to be released from the metering chamber when the valve is actuated, and a pressurizer that applies pressure to the pharmaceutical formulation in the metering chamber while the pharmaceutical formulation is being released from the metering chamber. In one version, the metering chamber is sized so that at least 2 mg, and preferably at least 5 mg, of the active agent is be aerosolized for delivery to a user during inhalation.

Abstract: An aerosolization apparatus comprises a container containing a pharmaceutical formulation, the pharmaceutical formulation comprising an active agent and a propellant. The aerosolization apparatus further comprises a metering chamber in communication with the container, the metering chamber adapted to hold a metered amount of the pharmaceutical formulation, a valve to allow the metered amount of the pharmaceutical formulation to be released from the metering chamber when the valve is actuated, and a pressurizer that applies pressure to the pharmaceutical formulation in the metering chamber while the pharmaceutical formulation is being released from the metering chamber. In one version, the metering chamber is sized so that at least 2 mg, and preferably at least 5 mg, of the active agent is be aerosolized for delivery to a user during inhalation.

Abstract: An aerosolization apparatus comprises a container containing a pharmaceutical formulation, the pharmaceutical formulation comprising an active agent and a propellant. The aerosolization apparatus further comprises a metering chamber in communication with the container, the metering chamber adapted to hold a metered amount of the pharmaceutical formulation, a valve to allow the metered amount of the pharmaceutical formulation to be released from the metering chamber when the valve is actuated, and a pressurizer that applies pressure to the pharmaceutical formulation in the metering chamber while the pharmaceutical formulation is being released from the metering chamber. In one version, the metering chamber is sized so that at least 2 mg, and preferably at least 5 mg, of the active agent is be aerosolized for delivery to a user during inhalation.

Abstract: Capsules (such as hard gelatin, cellulose and plastic capsules) containing pharmaceutical powders which are administered to a patient via inhalation are treated so as to increase the effective amount of the pharmaceutical agent reaching the respiratory system of the patient. The capsules are coated internally with a lubricant during manufacture and in one aspect, the method involves exposing the lubricant-coated inner surface of the capsule to a pharmaceutically acceptable solvent which dissolves the lubricant. Generally, the solvent is volatile, and bactericidal (e.g. ethanol). The pharmaceutical powder is inserted in the capsule following this washing procedure. Alternatively, the lubricant-coated capsule is dusted internally with a dusting agent such as a salt (e.g. sodium chloride) or a sugar (e.g. lactose, mannitol, trehalose or sucrose) prior to inserting the pharmaceutical powder inside the capsule.

Abstract: A device for the administration by inhalation of a medicament in powdered form comprises a medicament reservoir (3) and metering means for dispensing a dose of medicament from the reservoir (3), characterized in that the reservoir (3) comprises a compacted body of powdered medicament (10) and the metering means includes means (11) for abrading the compacted body (10).

Abstract: A compacted body of powdered medicament for use in a device for the administration by inhalation of a medicament in powdered form. The compacted body is made by compressing a loose powder containing the medicament in powdered form under pressure to create sufficient structural integrity in the body to permit metering of several unit doses of the medicament by abrasion of the body in the device.

Abstract: A compacted body of powdered medicament for use in a device for the administration by inhalation of a medicament in powdered form. The compacted body is made by compressing a loose powder containing the medicament in powdered form under pressure to create sufficient structural integrity in the body to permit metering of several unit doses of the medicament by abrasion of the body in the device.

Abstract: A method of treatment of a condition selected from the group comprising conjunctivitis, keratitis, `allergic eyes`, adenovirus infections, corneal homograft rejection, anterior uveitis, nasal polyps, vasomotor rhinitis, allergic manifestations of the nasopharynx, reversible obstructive airways disease, Crohn's disease, distal colitis and proctitis, which method comprises administration to a patient suffering from such a condition of a therapeutically effective amount of an aqueous solution containing, as active ingredient, 9-ethyl-6,9-dihydro-4,6-dioxo-10-propyl-4H-pyrano(3,2-g)quinoline-2,8-dica rboxylic acid or a pharmaceutically acceptable salt thereof. Also described are novel pharmaceutical compositions suitable for use in such methods of treatment.

Abstract: Particulate nedocromil sodium with a mass median diameter of from 5 to 10 .mu.m is useful as a medicament for inhalation.The particulate nedocromil sodium of the invention is particularly advantageous in that its dispersion, i.e. the proportion of particles which are capable of penetrating deep into the lung, is substantially greater than the dispersion of conventional powders having smaller mass median diameters.

Abstract: A method of compacting and administering a powdered inhalation medicament for use in an inhalation device includes compacting a body of loosely powdered inhalation medicament such that the degree of compaction is sufficient to hold the body together solely due to the force of compaction and placing the compacted body into the inhalation device and abrading the compacted body to obtain a plurality of unit doses of the medicament.

Abstract: A disposable device for the administration of powdered inhalation medicament is provided which comprises a rigid medicament reservoir (4) holding a unit dose of medicament (10) and having air inlet means (5,7) and medicament outlet means (8); and closure means (3) which are removable in use; wherein the medicament (10) held in the reservoir (4) is in loose powder form.

Abstract: Particulate nedocromil sodium with a mass median diameter of from 5 to 10 .mu.m is useful as a medicament for inhalation.The particulate nedocromil sodium of the invention is particularly advantageous in that its dispersion, i.e. the proportion of particles which are capable of penetrating deep into the lung, is substantially greater than the dispersion of conventional powders having smaller mass median diameters.

Abstract: A device for the administration by inhalation of a medicament in powdered form. The device includes a supply of the medicament in the form of a compacted body of powered medicament, a rotatable helical blade which abrades a desired quantity of the medicament from the compacted body, and a mouthpiece through which the abraded powder can be inhaled by the user of the device.

Abstract: There is described a pharmaceutical composition comprising nedocromil sodium and liposomes.There is also described an aqueous suspension comprising nedocromil sodium partitioned between a free aqueous phase and a liposome phase.There ae also described a method of making the compositions and their use in the manufacture of a medicament for the treatment of reversible obstructive airways disease.

Abstract: There are described new forms of nedocromil sodium, methods of producing these new forms and pharmaceutical formulations, especially pressurized inhalation aerosol formulations, containing finely divided nedocromil sodium. The formulations are indicated for the treatment of reversible obstructive conditions of the airways.

Abstract: There are described new forms of nedocromil sodium, methods of producing these new forms and pharmaceutical formulations, especially pressurized inhalation aerosol formulations, containing finely divided nedocromil sodium. The formulations are indicated for the treatment of reversible obstructive conditions of the airways.

Abstract: A method of treatment of a condition selected from the group comprising conjunctivitis, keratitis, ‘allergic eyes’, adenovirus infections, corneal homograft rejection, anterior uveitis, nasal polyps, vasomotor rhinitis, allergic manifestations of the nasopharynx, reversible obstructive airways disease, Crohn's disease, distal colitis and proctitis, which method comprises administration to a patient suffering from such a condition of a therapeutically effective amount of an aqueous solution containing, as active ingredient, 9-ethyl-6,9-dihydro-4,6-dioxo-10-propyl-4H-pyrano(3,2-g)quinoline-2,8-dicarboxylic acid or a pharmaceutically acceptable salt thereof. Also described are novel pharmaceutical compositions suitable for use in such methods of treatment.